BIOAGE LABS INC (BIOA)
Health Care · Clinical-stage biopharmaceutical / aging biology / metabolic diseases · NASDAQ
Clinical-stage biotech targeting aging biology to develop novel small-molecule therapeutics for metabolic and cardiovascular diseases, led by brain-penetrant NLRP3 inhibitor BGE-102.
What BIOAGE LABS INC does
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform uses differentiated human datasets to identify promising drug targets based on molecular changes that drive aging. Its lead program, BGE-102, is a brain-penetrant, orally available NLRP3 inhibitor being evaluated for metabolic and cardiovascular indications, with additional APJ receptor programs in preclinical and early clinical development.
Themes: Aging and longevity / geroscience, NLRP3 inhibitors, Metabolic disease therapeutics, Obesity and cardiovascular disease, Diabetic macular edema
Fundamentals
- Price$9.48 as of 2026-08-21 close
- Market cap$435M as of 2026-08-21
- 1-year return+110.7% 2025-08-21 close $4.50 → 2026-08-21 close $9.48
- P/En/a negative earnings
- Net margin-871.8% as of 2026-08-24
- ROE-29.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+91.0% as of 2026-08-24
- Beta2.11 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How BIOA compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How BIOAGE LABS INC looks technically
BIOAGE LABS INC (BIOA) is trading 43.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 226 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 30, in oversold territory (below 30). It made a new 20-day low about 16 trading days ago. It is 63.5% below its highest point of the past year. Trading volume is unusually light — only about 41% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 43.2% below its 200-day average, the long-term trend line — a long-term downtrend | -43.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $18.54 | $18.54 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.68 | $16.68 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 11.94. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 3 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 226 trading days ago — a "golden cross", a bullish long-term signal | 226 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control | 36.1 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 30, in oversold territory (below 30) | 29.9 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($9.48 to $11.94) — its "stochastic" reading is 0 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 0.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $25.95 | $25.95 |
|---|---|---|
| From the 52-week high | it is 63.5% below its 52-week high (its highest price of the past year) | -63.5% |
| Above the 52-week low | it is 116.4% above its 52-week low (its lowest price of the past year) | +116.4% |
| Below the 52-week high | it is 63.5% below its highest point of the past year | 63.5% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day low about 16 trading days ago | 16 sessions |
| All-time high | its highest closing price on record is $26.62 (set on 2024-10-22) | $26.62 |
| Given back of the 52-week move | over the past year its closes ranged ($4.42 to $25.10), and it has given back well over two thirds of its rise from last year’s low — 76% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.66 to $12.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 75.5% |
| From the all-time high | it is 64.4% below its all-time high | -64.4% |
| Nearest price level | it is trading 9.0% above a support level at $8.63 — a price it turned at twice since 2025-10-23, most recently on 2026-07-31. Since 2024-09-26 it has 4 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -9.0% |
| All-time low | its lowest closing price on record is $2.88 (set on 2025-04-09) | $2.88 |
| Above the all-time low | it is 229.2% above its all-time low | +229.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 97% of the past ~6 months) | 97th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.35 between its high and its low — about 14.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.35 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.30 and $22.63 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.30 – $12.96 – $22.63 |
| Typical daily range (% of price) | its price moves about 14.3% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 14.3% |
| Stretch from the 200-day average | it is trading 5.3 daily ranges below its 200-day average price (43.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.3 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 41% of its 30-day average | 0.41× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 5.1% above the previous close 14 sessions ago and has not traded back through the level it left behind at 9.04 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.1% |
| Gap filled | a 2.2% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -11.81% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 60.5 percentage points (the stock lost 58.1% while the market gained 2.3%) | -60.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 46.5 percentage points (the stock lost 43.4% while the market gained 3.1%) | -46.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 64.8 percentage points (the stock lost 53.8% while the market gained 11.1%) | -64.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 90.2 percentage points (the stock gained 110.7% while the market gained 20.5%) | +90.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 53% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 18.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -53.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 46% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $17.49 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -45.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $10.73 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -11.6% |
Price levels it has turned at before
BIOA last closed at $9.48 on 2026-08-21. Since 2024-09-26 it has turned at 4 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $8.63 | Support | 9.0% below the last close | turned there twice · 2025-10-23 to 2026-07-31 |
| $11.90 | Resistance | 25.6% above the last close | turned there twice · 2026-01-05 to 2026-08-07 |
| $5.07 | Support | 46.5% below the last close | turned there twice · 2025-08-29 to 2025-10-17 |
| $4.67 | Support | 50.7% below the last close | turned there four times · 2025-03-03 to 2025-09-16 |
| $17.93 | Resistance | 89.1% above the last close | turned there twice · 2024-11-18 to 2026-06-01 |
| $18.27 | Resistance | 92.8% above the last close | turned there twice · 2026-01-26 to 2026-03-13 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $11.94.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · lagging the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$35.63 range $20.00 – $73.00; median $30.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BIOA
- Consensus EPS estimate-$0.6076 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: BGE-102 is in early-stage clinical trials with uncertain efficacy, safety, and regulatory path; unexpected adverse events or lack of efficacy could halt development or delay commercialization.","Regulatory and approval risk: Dependent on FDA designations and approvals; shifting FDA priorities, geopolitical factors, and regulatory changes could impact timing and success of clinical programs.","Cash burn and funding risk: Unprofitable with significant operating expenses; continued ability to fund clinical trials and operations dependent on capital availability and ability to raise additional funding."]
What changed in the latest 10-Q
AI-assisted comparison of BIOA's 10-Q filed 2026-05-08 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for 'Management's Discussion and Analysis of Financial Condition and Results of Operations' changed from 19 (filed 2025-11-06) to 18 (filed 2026-05-08)
- Page number for 'Quantitative and Qualitative Disclosures About Market Risk' changed from 33 (filed 2025-11-06) to 28 (filed 2026-05-08)
- Page number for 'Controls and Procedures' changed from 33 (filed 2025-11-06) to 28 (filed 2026-05-08)
- Page number for 'PART II. OTHER INFORMATION' changed from 34 (filed 2025-11-06) to 29 (filed 2026-05-08)
- Page number for 'Legal Proceedings' changed from 34 (filed 2025-11-06) to 29 (filed 2026-05-08)
- Notes:
- Only table of contents page numbers are visible in the provided text excerpts; substantive MD&A content changes cannot be assessed from this comparison
Risk Factors
- Added:
- Added reference to 'political instability and military hostilities in multiple geographies, such as the conflicts in Ukraine, Venezuela, Iran, tensions between China and Taiwan and the possibility of a wider Middle Eastern, European or global conflict' (filed 2026-05-08)
- Added phrase 'any future federal government shutdowns' (filed 2026-05-08)
- Removed:
- Removed reference to 'the ongoing federal government shutdown' (was in filed 2025-11-06)
- Removed phrase 'global regional conflicts' (was in filed 2025-11-06)
- Reworded:
- Changed 'and global regional conflicts on our operations' to 'political instability and military hostilities in multiple geographies, such as the conflicts in Ukraine, Venezuela, Iran, tensions between China and Taiwan and the possibility of a wider Middle Eastern, European or global conflict, on our operations' (filed 2026-05-08 vs 2025-11-06)
- Changed 'the ongoing federal government shutdown and any future federal government shutdowns' to 'any future federal government shutdowns' - removed reference to ongoing shutdown as current condition (filed 2026-05-08)
- Notes:
- The comparison focuses on the forward-looking statements section provided; the actual full Risk Factors section content was not included in either document excerpt
- Table of contents page numbers changed (Item 1A Risk Factors moved from page 34 to page 29), but this reflects formatting/pagination changes rather than content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($2M) — 1 selling insider
- Last 180 days0 buys · 4 sells ($2M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-30. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BIOA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding BIOA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,464,736
- Reported value $60,598,232
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BIOA had 2,565,606 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BIOA had 5.59% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.89 days to cover at the same settlement.
- Reported short interest (shares) 2,565,606
- Short interest (% of shares outstanding) 5.59%
- Prior settlement (shares) 2,451,099
- Reported change 4.67%
- Days to cover (reported) 1.89
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Novo Nordisk (NVO)
- Viking Therapeutics
- Structure Therapeutics
- Rgenix
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BIOA vs…
Frequently asked questions
What does BIOAGE LABS INC (BIOA) do?
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform uses differentiated human datasets to identify promising drug targets based on molecular changes that drive aging.
What sector is BIOAGE LABS INC (BIOA) in?
BIOAGE LABS INC (BIOA) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical / aging biology / metabolic diseases. It trades on NASDAQ.
Who are BIOAGE LABS INC's (BIOA) competitors?
Notable peers of BIOAGE LABS INC (BIOA) include Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics and Rgenix. This peer set is informational only — not financial advice.
Is BIOAGE LABS INC (BIOA) overbought or oversold right now?
BIOAGE LABS INC (BIOA) is currently in oversold territory (its 14-day RSI is 30, below 30) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BIOA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.